The chronic kidney disease drug development landscape is evolving at an unprecedented pace, driven by breakthrough approvals, billion-dollar mergers and acquisitions, and increasing regulatory support ...

Shares of AstraZeneca Pharma India Ltd closed at ₹7,450 on the BSE, down 1.29% ahead of the earnings announcement.

Tom Equels, CEO of AIM ImmunoTech and Professor Casper H.J. van Eijck, MD, PhD, Pancreato-biliary Surgeon at Erasmus MC, discuss the Phase 1b/2 clinical trial involving AIM's Ampligen® (rintatolimod) ...

National Institutes of Health (NIH) scientists and their colleagues report that a single dose of a broadly neutralizing antibody (bnAb) administered prior to virus exposure protects macaques from ...

Glox Therapeutics has appointed of Michael Murray as chair of its board. He will work with the leadership team to accelerate ...

The Policy Exchange has put the cost of inquiries, court cases, inquests and compensation payouts so far at between ...

Pliant Therapeutics paused its phase 2b/3 trial of bexotegrast for idiopathic pulmonary fibrosis due to DSMB recommendations.

Former UK Prime Minister Boris Johnson recently spoke as part of the Society of the Four Arts' Esther B. O’Keeffe Speaker ...

AstraZeneca’s planned vaccine hub for Liverpool is off the table - business editor Karl Matchett and Whitehall editor Kate ...

Researchers discovered the importance of an enzyme that promotes growth of certain lung cancers. Lung cancer is a ...

Strength in the pharmaceutical major’s oncology business offset weak China sales, but the company has warned of a potential ...

People with metastatic cancer who regularly report their symptoms via a home-based electronic monitoring system experienced ...